Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells 6,702 Shares of Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 6,702 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $146.03, for a total value of $978,693.06. Following the completion of the sale, the chief executive officer now owns 203,354 shares of the company's stock, valued at approximately $29,695,784.62. This represents a 3.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, March 5th, Steven Leonard Chapman sold 87,272 shares of Natera stock. The stock was sold at an average price of $143.40, for a total value of $12,514,804.80.
• On Wednesday, January 29th, Steven Leonard Chapman sold 13,685 shares of Natera stock. The stock was sold at an average price of $165.87, for a total value of $2,269,930.95.
• On Wednesday, January 22nd, Steven Leonard Chapman sold 78,553 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41.

Natera Stock Up 1.0 %

NASDAQ:NTRA traded up $1.52 during trading hours on Friday, hitting $151.15. 3,420,538 shares of the company's stock traded hands, compared to its average volume of 1,339,250. The firm has a market cap of $20.43 billion, a P/E ratio of -85.88 and a beta of 1.80. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock's fifty day moving average price is $161.23 and its two-hundred day moving average price is $150.01.

Remove Ads

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. On average, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of NTRA. LRI Investments LLC acquired a new position in Natera in the 4th quarter worth about $29,000. Blue Trust Inc. increased its position in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after purchasing an additional 97 shares during the last quarter. Versant Capital Management Inc boosted its stake in shares of Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after acquiring an additional 166 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after acquiring an additional 261 shares in the last quarter. Finally, Principal Securities Inc. boosted its stake in shares of Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after acquiring an additional 59 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Barclays assumed coverage on Natera in a report on Thursday, January 23rd. They issued an "overweight" rating and a $200.00 target price on the stock. Morgan Stanley raised their price objective on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. The Goldman Sachs Group raised their price objective on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Robert W. Baird raised their price target on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Finally, StockNews.com upgraded Natera from a "sell" rating to a "hold" rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $178.12.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.